Experienced in Glucose-6-Phosphate Dehydrogenase Deficiency

Deven Juneja

New Delhi, DL, IN 
Experienced in Glucose-6-Phosphate Dehydrogenase Deficiency
New Delhi, DL, IN 
OverviewLocationsClinical Research

Overview

Deven Juneja practices in New Delhi, India. Juneja is rated as an Experienced expert by MediFind in the treatment of Glucose-6-Phosphate Dehydrogenase Deficiency. Their top areas of expertise are Sepsis, Pneumomediastinum, Fungal Arthritis, Methemoglobinemia, and Fasciotomy.

Their clinical research consists of co-authoring 95 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Glucose-6-Phosphate Dehydrogenase Deficiency.

Locations

New Delhi, DL, India
Other Locations
Delhi, DL, India
Saket, MP, India
Hyderabad, AP, India
Hyderabad, TG, India

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris
Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: SCY-078
Study Phase: Phase 3
A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
Enrollment Status: Unknown
Publish Date: July 22, 2020
Intervention Type: Drug, Other
Study Drug: Convalescent plasma
Study Phase: Phase 2
View 1 Less Clinical Trial

95 Total Publications

Author Response: Hidden Constraints: Addressing Unreported Limitations in Plasmapheresis Studies for Hypertriglyceridemia-associated Pancreatitis.
Author Response: Hidden Constraints: Addressing Unreported Limitations in Plasmapheresis Studies for Hypertriglyceridemia-associated Pancreatitis.
Journal: Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
Published: October 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Juneja's expertise for a condition
ConditionClose
      View All 40 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile